


## **CLAIMS**

1. An amorphous form of Compound 1,



**Compound 1**


- wherein the amorphous form has an enantiomeric excess value of at least 90%.
2. The amorphous form of claim 1, wherein the amorphous form has a mid-point temperature of a glass transition temperature of about 79.7° C.
  3. The amorphous form of claim 2, wherein the amorphous form has an enantiomeric excess value of at least 97%.
  4. The amorphous form of claim 3, wherein the amorphous form has a purity of at least 99.3%.
  5. The amorphous form of claim 4, wherein the amorphous form has a purity of at least 99.5%.
  6. A pharmaceutical composition comprising the amorphous form of claim 5 and a pharmaceutically acceptable excipient.
  7. The pharmaceutical composition of claim 6, wherein the composition is in a single unit form.
  8. The pharmaceutical composition of claim 7, wherein the single unit form comprises about 40 mg or about 80 mg of the amorphous form of Compound 1.
  9. The pharmaceutical composition of claim 6, wherein the pharmaceutical composition comprises about 160 mg of the amorphous form of Compound 1.
  10. Use of the amorphous form of claim 1 in the manufacture of a medicament for treating a B-cell proliferative disease in a subject, wherein the B-cell proliferative disease is selected from a group consisting of chronic lymphocytic leukemia, small lymphocytic

lymphoma, mantle cell lymphoma, Waldenström's macroglobulinemia, marginal zone lymphoma, and follicular lymphoma.

11. The use of claim 10, wherein the amorphous form of Compound 1 is to be administered at a dose of 40 mg/day to 320 mg/day.
12. The use of claim 10, wherein the amorphous form of Compound 1 is to be administered at a dose of 160 mg twice a day (BID).
13. The use of claim 10, wherein the amorphous form of Compound 1 is to be administered at a dose of 320 mg once a day (QD).
14. The use of claim 10, wherein the B-cell proliferative disease is chronic lymphocytic leukemia.
15. The use of claim 10, wherein the B-cell proliferative disease is small lymphocytic lymphoma.
16. The use of claim 10, wherein the B-cell proliferative disease is mantle cell lymphoma.
17. The use of claim 16, wherein the subject has received at least one prior therapy.
18. The use of claim 10, wherein the B-cell proliferative disease is Waldenström's macroglobulinemia.
19. The use of claim 10, wherein the B-cell proliferative disease is marginal zone lymphoma.
20. The use of claim 19, wherein the subject has received at least one prior therapy.
21. The use of claim 20, wherein the marginal zone lymphoma is relapsed or refractory marginal zone lymphoma.
22. The use of claim 10, wherein the B-cell proliferative disease is follicular lymphoma.
23. The use of claim 10, wherein the amorphous form of Compound 1 is to be administered orally.

24. A lyophilized amorphous form of Compound 1,

**Compound 1**



25. The lyophilized amorphous form of claim 24, wherein the lyophilized amorphous form has an enantiomeric excess value of at least 97%.
26. The lyophilized amorphous form of claim 25, wherein the lyophilized amorphous form has a purity of at least 99.3%.
27. The lyophilized amorphous form of claim 26, wherein the lyophilized amorphous form has a purity of at least 99.5%.